Finerenone, a non-steroidal selective mineralocorticoid receptor antagonist that induces natriuresis with reduced hyperkalaemia compared with steroidal antagonists, potentially provides anti-inflammatory and anti-fibrotic effects in DKD [153]. The gene discussed is NR3C2; the disease is diabetic kidney disease.